EADV Congress Hilights 2024
Acknowledgements Privacy Policy Cookie Policy How Can We Help?
EADV 2024 Highlights
Available on the Medfyle App

This activity is supported by an unrestricted educational sponsorship from Lilly

Welcome to the EADV 2024 Highlights!


The Highlights offer a selection of the newest and most relevant data presented at the EADV Congress 2024. Enjoy this opportunity to learn about the significant advances and breakthroughs in dermatology research and care.

Prof. Antonio Costanzo 

EADV 2024 Highlights Editor

Faculty interviews

Gain valuable insights from an international panel of experts.
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See all

Oral presentations

Missed the full presentation? Read at-a-glance summaries from a selection of oral presentations. Don’t forget to download the slides!

Alopecia Areata

Deuruxolitinib for AA

Mirmirani P, Mesinkovska N, King B, et al.

THRIVE-AA2 data were shared at EADV 2023. Now, new pooled data from -AA1 and -AA2 look specifically at changes in patient-reported hair satisfaction during deuruxolitinib treatment for severe AA.

EADV 2024 - Oral session

Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials

Read more

eadv24-op01-mirmirani-deuruxolitinib-for-aa
Atopic Dermatitis

Lebrikizumab in AD

Thaçi D, Irvine A, Simpson E, et al.

A late-breaking abstract from EADV 2024 explores the efficacy and safety of lebrikizumab up to 3 years in patients with atopic dermatitis, showing most responders maintain clear or almost clear skin with continuous treatment.

EADV 2024 - Oral session

Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial

Read more

eadv24-op02-thaci-lebrikizumab-in-ad
Hidradenitis Suppurativa

Izokibep in hidradenitis suppurativa

Papp KA, Bechara FG, Porte ML, et al.

This late-breaking abstract at EADV 2024 showcases the efficacy and safety of izokibep – a novel IL-17A inhibitor – in moderate-to-severe hidradenitis suppurativa.

EADV 2024 - Oral session

Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study

Read more

eadv24-op03-papp-izokibep-in-hidradenitis-suppurativa
See More

Posters

Read at-a-glance summaries from a selection of poster presentations.

Alopecia Areata

Baricitinib in AA

Senna MM, Mostaghimi A, Ohyama M, et al.

Long-term data are available for baricitinib in other indications – with integrated safety analyses up to 9.3 years. New data in severe AA examine 3-year efficacy outcomes with continued treatment in initial responders.

EADV 2024 - Poster session

Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2

Read more

eadv24-pp01-baricitinib-in-aa
Hidradenitis Suppurativa

BE HEARD: Bimekizumab in HS

Ingram JR, Daveluy S, Prens E, et al.

Hidradenitis suppurativa is a chronic and flaring skin disease. New pooled clinical trial data presented at EADV 2024 suggest targeted therapy with bimekizumab could help reduce flares.

EADV 2024 - Poster session

Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Read more

eadv24-pp02-be-heard-bimekizumab-in-hs
Hidradenitis Suppurativa

Semaglutide in hidradenitis suppurativa

Lyons D, Nathan A, Pender E, et al.

Hidradenitis suppurativa is a debilitating condition with an inflammatory component – and a link to obesity. New data presented at EADV 2024 explore the role of modern weight-loss options to help improve quality of life and reduce flares.

EADV 2024 - Poster session

Semaglutide for weight loss in obese patients as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life

Read more

eadv24-pp03-lyons-semaglutide-in-hidradenitis-suppurativa
See More

Deep Dives

Watch on-demand videos, led by experts, to dive deeper into subjects of special interest.

Feedback

Want more dermatology content?

Subscribe to the newsletter and receive:
  • The EADV 2024 Highlights slide kit
  • Access to the latest news from international conferences
  • Bite-sized summaries of practice-changing publications

Ask the Expert

Have a question? Submit it below.
A selection of the most interesting questions will be answered in a new video. You will receive an email when answers will be published.